A real-world study finds elderly psoriasis patients treated with IL-17 and IL-23 inhibitors achieve comparable long-term ...

Joni Kazantzis didn't think her psoriasis would turn into psoriatic arthritis. But the new diagnosis taught her—and her ...

Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...

Living with psoriasis presents unique challenges, but with the right skincare routine, you can maintain healthy skin.

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, "We are excited to share the results on this novel ...

Artelo Biosciences, Inc. (NASDAQ:ARTL) on Monday announced new research published in the peer-reviewed Journal of ...